Aveanna Healthcare Holdings Inc. (AVAH) SEC Filings & Earnings Calls
EquiReason read 23 Aveanna Healthcare Holdings Inc. SEC filings in the last 12 months. Latest: 8-K on 2026-10-02 — Director Steven E. Rodgers resigned from the Board effective immediately, with no disagreement with the company. Independent director on Audit and Compensation Committees..
Source: SEC EDGAR filings · figures as of 2026-07-04 · read by EquiReason
- Market cap
- 2.9B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
2 Oct 20268-K · 5.02Director Steven E. Rodgers resigned from the Board effective immediately, with no disagreement with the company. Independent director on Audit and Compensation Committees.open
Risks flagged
Loss of independent director with committee roles may reduce board oversight temporarily.
“Mr. Rodgers was an independent director, serving on both the Audit Committee and the Compensation Committee.” · word for word
24 Aug 20268-K · 8.01Aveanna Healthcare secondary offering of 15M shares at $11.75 by selling stockholders; company received no proceeds; potential overhang from additional 2.25M share option.open
Figures in the filing · each found in the filing text
| Secondary Offering Shares · Q3-2026 | 15,000,000 | |
| Public Offering Price · Q3-2026 | $11.75 | |
| Over-Allotment Option Shares · Q3-2026 | 2,250,000 |
Risks flagged
Insider selling via secondary offering signals potential lack of confidence or need for liquidity by major shareholders, increasing dilution risk for existing shareholders.
“Selling stockholders include affiliates of J.H. Whitney Equity Partners VII, LLC and certain current and former directors and officers.”
13 Aug 20268-K · 2.02, 7.01Revenue $670M (+14% y/y); Net Income $40M (+49% y/y); Adjusted EBITDA $95M (+8% y/y); Guidance: Revenue >$2.68B (from $2.63-2.65B); Adj. EBITDA >$365M (from $338-342M)earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q2-2026 | $671M | +14% y/y |
| Net Income · Q2-2026 | $40M | +49% y/y |
| Adjusted EBITDA · Q2-2026 | $95M | +8% y/y |
| Gross Margin · Q2-2026 | $219M | +4% y/y |
| Cash and Cash Equivalents · Q2-2026 | $97M | |
| Free Cash Flow · H1-2026 | $75M | |
| Total Indebtedness · Q2-2026 | $1.48B | |
| Net Income per Diluted Share · Q2-2026 | $0.18 | +39% y/y |
| Adjusted Net Income per Diluted Share · Q2-2026 | $0.22 | +22% y/y |
Guidance
Revenue >$2.68B (from $2.63-2.65B); Adj. EBITDA >$365M (from $338-342M)
Full-year 2026 guidance raised significantly: Revenue >$2.68B (from $2.63-2.65B), Adj. EBITDA >$365M (from $338-342M), reflecting strong H1 performance and confidence in outlook.
Risks flagged
Gross margin rate declined from 35.8% to 32.6% due to mix shift or cost pressures.
“Gross margin was 32.6% of revenue vs 35.8% in prior year period.”
High leverage with total indebtedness of $1.48B; interest rate exposure partially hedged.
“Total indebtedness $1,483.4M; interest rate caps on $1.4B notional.”
13 Aug 202610-QAveanna Healthcare reported Q2 2026 revenue growth of 13.7% YoY, but gross margin declined 3.2pp due to labor cost inflation; net income increased 49.1% YoY driven by lower interest expense.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q2-2026 | $670M | +14% y/y |
| Gross margin · Q2-2026 | 32.6% | |
| Adjusted EBITDA · Q2-2026 | $95M | +8% y/y |
| Net income · Q2-2026 | $40M | +49% y/y |
| Operating cash flow · H1-2026 | $85M | +99% y/y |
| PDS Hours · PDS · Q2-2026 | 12,413,000 | +12% y/y |
| PDS Revenue Rate · PDS · Q2-2026 | $44.62 | +1% y/y |
| PDS Cost of Revenue Rate · PDS · Q2-2026 | $31.74 | +7% y/y |
| PDS Spread Rate · PDS · Q2-2026 | $12.88 | -10% y/y |
| HHH Total Episodes · HHH · Q2-2026 | 14,700 | +19% y/y |
Risks flagged
Gross margin compression from labor cost inflation
“The 7.8% increase in cost of revenue rate primarily resulted from higher caregiver labor costs, including the pass-through of reimbursement rate increases and higher general and professional liability reserves in the second quarter of 2026.” · word for word
Integration risk from acquisitions
“Acquisition-related costs were $4.4 million for the three-month period ended July 4, 2026, as compared to $3.4 million for the three-month period ended June 28, 2025.” · word for word
Interest rate derivative exposure
“We realized a $5.4 million decrease in non-cash valuation losses associated with interest rate derivatives resulting from changes in market expectations of future interest rates as of the comparable quarter-end valuation date, partially offset by a $2.4 million decrease in net settlements with interest rate derivative counterparties as interest rates decreas”
7 Aug 20268-K · 5.02Reported a director or officer change (departure, election, appointment or pay arrangement)open
Risks flagged
Loss of independent director with clinical quality expertise; minimal near-term risk.
“Resignation of Chair of Clinical Quality Committee; no operational disagreement.”
2 Jun 20268-K · 8.01Acquisition cost $176Mopen
Figures in the filing · each found in the filing text
| acquisition cost · Q2-2026 | $176M |
Guidance
Guidance updated to reflect acquisition contribution, implying revenue growth but no margin detail.
Risks flagged
Integration risk from acquisition; potential for higher leverage or operational disruption.
“acquisition funded with cash on hand; integration of Family First operations may strain resources”
28 May 20268-K · 8.012026 Term Loans $1.32B; 2026 Refinancing Revolving Credit Facility $250M; interest rate margin reduction 0.5open
Figures in the filing · each found in the filing text
| 2026 Term Loans · 2026-05-26 | $1.32B | |
| 2026 Refinancing Revolving Credit Facility · 2026-05-26 | $250M | |
| interest rate margin reduction · 2026-05-26 | 0.5% |
Risks flagged
Debt repricing reduces interest expense, but leverage remains high.
“repricing of the facilities” · word for word
14 May 202610-QRevenue $648M (+16% y/y); Net income $42M (+702% y/y); Operating cash flow $4Mopen
Figures in the filing · each found in the filing text
| Revenue · Q1-2026 | $648M | +16% y/y |
| Net income · Q1-2026 | $42M | +702% y/y |
| Operating cash flow · Q1-2026 | $4M | |
| Cash and cash equivalents · 2026-04-04 | $189M | |
| Gross margin · Q1-2026 | $205M | +12% y/y |
| PDS Revenue · Private Duty Services · Q1-2026 | $536M | +16% y/y |
| HHH Revenue · Home Health & Hospice · Q1-2026 | $67M | +17% y/y |
| MS Revenue · Medical Solutions · Q1-2026 | $46M | +7% y/y |
| Acquisition-related costs · Q1-2026 | $3M |
Risks flagged
Regulatory investigation risk
“The Company has received grand jury subpoenas from the U.S. Department of Justice, Antitrust Division, requiring production of documents pertaining to nurse wages, reimbursement rates, and hiring activities.” · word for word
Medicaid reimbursement risk
“Changes to Medicaid to be implemented under the One Big Beautiful Bill Act could impact funding and reimbursement rates.” · word for word
Labor cost pressure
“Shortages in qualified employees and management and competition for qualified personnel.” · word for word
High leverage risk
“Total long-term obligations of $1,297.2 million net of unamortized debt issuance costs as of April 4, 2026.”
14 May 20268-K · 2.02, 7.01Revenue $648M (+16% y/y); Net income $42M (+702% y/y); Adjusted EBITDA $84M (+25% y/y); Guidance: Revenue guidance raised by $20M midpoint; Adj EBITDA guidance raised by $10M midpointearningsopen
Figures in the filing · each found in the filing text
| Revenue · Q1-2026 | $648M | +16% y/y |
| Net income · Q1-2026 | $42M | +702% y/y |
| Adjusted EBITDA · Q1-2026 | $84M | +25% y/y |
| Revenue guidance (FY2026) · FY2026 | $2.57B |
Guidance
Revenue guidance raised by $20M midpoint; Adj EBITDA guidance raised by $10M midpoint
Raised FY2026 revenue and adjusted EBITDA guidance reflecting strong Q1 performance and positive momentum.
Risks flagged
Regulatory approval dependency for Family First Homecare transaction may delay expected synergies.
“While we finalize the regulatory approval process on the Family First Homecare transaction” · word for word
17 Apr 2026DEF 14ARevenue $2.43B (+20% y/y); Adjusted EBITDA $321M (+75% y/y); Operating cash flow $126Mopen
Figures in the filing · each found in the filing text
| Revenue · FY2025 | $2.43B | +20% y/y |
| Adjusted EBITDA · FY2025 | $321M | +75% y/y |
| Operating cash flow · FY2025 | $126M | |
| Free cash flow · FY2025 | $131M | |
| Net income · FY2025 | $225M |
Risks flagged
Regulatory investigation risk
“The Company has received grand jury subpoenas from the U.S. Department of Justice, Antitrust Division, requiring production of documents pertaining to nurse wages, reimbursement rates, and hiring activities.”
Medicaid reimbursement risk
“Changes to Medicaid to be implemented under the One Big Beautiful Bill Act could impact funding and reimbursement rates.”
High leverage risk
“Total long-term obligations of $1,297.2 million net of unamortized debt issuance costs as of April 4, 2026.”
Labor cost pressure
“Shortages in qualified employees and management and competition for qualified personnel.”
19 Mar 202610-KRisks named: Medicare Reimbursement Rate Cut, Medicaid Funding Cuts, Labor Cost Inflation, Managed Care Rate Pressureopen
Risks flagged
Medicare Reimbursement Rate Cut
“On November 28, 2025, CMS released a final rule for fiscal year 2026 that cuts Medicare reimbursement rates by 1.3%.” · word for word
Medicaid Funding Cuts
“The OBBBA includes, among other provisions, certain funding cuts to the Medicaid program, such as a reduction of funding for states choosing to expand the state’s Medicaid program, and updated eligibility requirements for Medicaid beneficiaries.” · word for word
Labor Cost Inflation
“In recent years, the labor markets have been challenging as a result of both shortages in workforce and inflationary wage pressures, which have constrained our ability to recruit and retain caregivers to meet patient demand.” · word for word
Managed Care Rate Pressure
“Managed care organizations, such as health maintenance organizations (HMOs) and preferred provider organizations (PPOs), and other third-party payers continue to consolidate, which enhances their ability to influence the delivery of healthcare services.” · word for word
Cybersecurity Breach
“We, our patients, and our third-party service providers have been the victims of these types of threats, attacks and security breaches in the past.” · word for word
19 Mar 20268-K · 2.02, 7.01Revenue $662M (+27% y/y); Net income $179M (+512% y/y); Adjusted EBITDA $85M (+54% y/y); Guidance: Revenue $2.54-$2.56B; Adjusted EBITDA $318-$322Mearningsopen
Figures in the filing · each found in the filing text
| Revenue · Q4-2025 | $663M | +27% y/y |
| Net income · Q4-2025 | $179M | +512% y/y |
| Adjusted EBITDA · Q4-2025 | $85M | +54% y/y |
| Gross margin · Q4-2025 | 32.2% | |
| Net income per diluted share · Q4-2025 | $0.80 | +471% y/y |
| Adjusted net income per diluted share · Q4-2025 | $0.17 | +240% y/y |
| Revenue (Full Year) · FY2025 | $2.43B | +20% y/y |
Guidance
Revenue $2.54-$2.56B; Adjusted EBITDA $318-$322M
Maintained Full Year 2026 Revenue guidance of between $2.54 and $2.56 billion; Maintained Full Year 2026 Adjusted EBITDA guidance of between $318 and $322 million
Risks flagged
Gross margin slightly declined from 33.0% to 32.2% YoY, indicating potential cost pressure.
“Gross margin was $213.3 million, or 32.2% of revenue, for the three-month period ended January 3, 2026, as compared to $171.7 million, or 33.0% of revenue, for the three-month period ended December 28, 2024” · word for word
12 Mar 20268-K · 8.01Cash purchase price $176Mopen
Figures in the filing · each found in the filing text
| cash purchase price · Q2-2026 | $176M |
Risks flagged
Antitrust review and customary closing conditions may delay or prevent closing.
“Transaction subject to HSR Act waiting period and absence of any law or order preventing the transaction.”
27 Feb 20268-K · 5.02Reported a director or officer change (departure, election, appointment or pay arrangement)open
Risks flagged
Board composition change may signal governance transition, but no disagreement indicates low risk.
“Resignation not due to disagreement; no other material changes disclosed.”
20 Feb 20268-K · 5.02CEO annual base salary $750,000.00; CFO annual base salary $500,000.00; CLO annual base salary $450,000.00open
Figures in the filing · each found in the filing text
| CEO annual base salary · FY2026 | $750000.00 | |
| CFO annual base salary · FY2026 | $500000.00 | |
| CLO annual base salary · FY2026 | $450000.00 |
Risks flagged
Generous severance and change-in-control benefits could create retention costs or misalignment.
“CEO severance of 2x salary plus bonus outside CIC, 2.5x inside CIC; similar for other NEOs.”
14 Jan 20268-K · 2.02, 7.01Revenue $2.44B; revenue guidance $2.55B; Guidance: FY2025 revenue raised to $2.425-2.445B from >$2.375B; Adj. EBITDA raised to $318-322M from >$300Mearningsopen
Figures in the filing · each found in the filing text
| revenue · FY2025 | $2.44B | |
| revenue guidance · FY2026 | $2.55B |
Guidance
FY2025 revenue raised to $2.425-2.445B from >$2.375B; Adj. EBITDA raised to $318-322M from >$300M
Raised FY2025 guidance on both revenue and Adjusted EBITDA; initial FY2026 guidance implies continued growth.
Risks flagged
Preliminary results subject to audit adjustments; reliance on reimbursement rates.
“Financial statements not yet available; preliminary estimates subject to change.”
14 Nov 20258-K · 1.01, 5.02Entered a material definitive agreement (acquisition, partnership, or major contract); reported the departure of a director or principal officer (CEO/CFO change)open
Risks flagged
Governance changes; executive share transfer restrictions may impact liquidity.
“certain executives may only sell, transfer, assign, pledge or otherwise directly or indirectly dispose of shares of Common Stock to the extent that such Transfer is pre-approved by the Compensation Committee”
6 Nov 202510-QAveanna reported strong Q3 2025 results with 22.2% revenue growth and turned profitable, driven by Private Duty Services segmentearningsopen
Figures in the filing · each found in the filing text
| Revenue · Consolidated · Q3-2025 | $622M | +22% y/y |
| Gross Margin · Consolidated · Q3-2025 | 32.6% | |
| Net Income · Consolidated · Q3-2025 | $14M | |
| PDS Revenue · Private Duty Services · Q3-2025 | $514M | +26% y/y |
| HHH Revenue · Home Health & Hospice · Q3-2025 | $62M | +15% y/y |
| MS Revenue · Medical Solutions · Q3-2025 | $45M | -1% y/y |
Risks flagged
Legal and regulatory investigations
“The Company is fully cooperating with the Antitrust Division with respect to this investigation, and management believes that a loss event is not probable.” · word for word
Insurance reserve exposure
“Insurance reserves totaling $90.2 million were included on the interim unaudited consolidated balance sheets”
6 Nov 20258-K · 2.02, 7.01Revenue $622M (+22% y/y); Gross margin $203M (+27% y/y); Net income $14M; Guidance: FY2025 revenue >$2.375B (from >$2.3B); Adjusted EBITDA >$300M (from >$270M)earningsopen
Figures in the filing · each found in the filing text
| Revenue · total · Q3-2025 | $622M | +22% y/y |
| Gross margin · total · Q3-2025 | $203M | +27% y/y |
| Net income · total · Q3-2025 | $14M | |
| Adjusted EBITDA · total · Q3-2025 | $80M | +68% y/y |
| Revenue · total · 9M-2025 | $1.77B | +18% y/y |
| Gross margin · total · 9M-2025 | $597M | +29% y/y |
| Net income · total · 9M-2025 | $46M | |
| Adjusted EBITDA · total · 9M-2025 | $236M | +84% y/y |
| Cash and cash equivalents · total · Q3-2025 | $146M | |
| Free cash flow · total · 9M-2025 | $86M |
Guidance
FY2025 revenue >$2.375B (from >$2.3B); Adjusted EBITDA >$300M (from >$270M)
Raised full-year guidance on both revenue and Adjusted EBITDA, reflecting strong operational momentum and successful integration.
Risks flagged
High leverage with total debt of $1.49B; interest rate exposure partially hedged.
“Total indebtedness of $1,490.0 million; interest rate swaps and caps in place.” · word for word
Integration risk from Thrive Skilled Pediatric Care acquisition.
“Integration of Thrive Skilled Pediatric Care is on track to be completed by the end of the year.” · word for word
Aveanna Healthcare Holdings Inc. — questions
- What did Aveanna Healthcare Holdings Inc. file recently?
- 23 SEC filings in the last 12 months. Latest: 8-K on 2026-10-02 — Director Steven E. Rodgers resigned from the Board effective immediately, with no disagreement with the company. Independent director on Audit and Compensation Committees.
Every figure on this page comes from Aveanna Healthcare Holdings Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.